University of Minnesota. Driven to Discover.
Narrow results
(CIDRAP News) – A vaccine designed to offer protection against many strains of influenza viruses appeared safe in low doses and triggered a satisfactory immune response in a phase 1 clinical trial, the vaccine's developer announced recently.
Get news & practices.
Sign up now»
Unrestricted financial support provided by
Become an underwriter»